VesiNex: HMC green nanomanufacturing platform for stable nanoliposomal carriers
Redefining nanomanufacturing
HMC: Hybrid Multiphasic Carriers.
A green platform that adaptively nano-encapsulates sensitive actives: ambient-temperature, solvent-free, single-vessel and scalable.
GentleEco-friendlyCost-effective
Manufacturing redesigned for sensitive actives.
One carrier holds hydrophilic, lipophilic and amphiphilic actives together, each protected from oxidation.
HMC avoids the heat, solvents and high-energy steps of conventional routes. Its gentle, low-energy process keeps sensitive actives intact.
Outcomes
- Processed at ambient temperature
- Free of organic solvents
- Single-vessel, low-energy process
- Ambient-stable, with no cold chain
- Fully redispersible after storage
Intellectual property Patent application AU 2024219996 (view on the public register; opens in a new tab), filed 2024. Two further filings in preparation.
Proven in commercial production.
HMC is proven in a registered multi-nutrient liquid that carries omega-3 with vitamins C, D3 and E. HMC products have been on the market since 2022, taken from laboratory to commercial production and made at room temperature, without solvents, in a single vessel.
EPA and DHA held after six months
Share of the initial value, %, at 0, 3 and 6 months
| Month | EPA, % of initial | DHA, % of initial |
|---|---|---|
| 0 | 100.0 | 100.0 |
| 3 | 99.3 | 99.2 |
| 6 | 99.2 | 98.9 |
Track record
- Registered food supplementLicensed in its launch market, with the current registration valid to 2027.
- Eurasian Economic Union (EAEU) state registration, 2024Two-year shelf life, stored below 25 °C.
- Export free-sale certificate, 2024Confirms approval for marketing in its launch market.
- Microbiology and heavy metals within specificationIndependent laboratory tests on the 2021 and 2022 batches.
Multiphasic by design
HMC carriers are multiphasic: nanoliposomes, vesicles and nano-emulsion droplets coexist, which is how one liquid carries water-soluble and oil-soluble actives together.
Nanoliposome-scale vesicles
Nano-emulsion droplets
Larger vesicles
Lamellar structures
Why HMC is hard to copy.
- Know-how held as a trade secretThe manufacturing process is not disclosed and is shared only under NDA, within a licence.
- Proven at commercial scaleHMC has moved beyond the laboratory into registered commercial production, while most gentle, solvent-free routes have remained at laboratory scale.
- Multiphasic co-deliveryWater-soluble and oil-soluble actives are carried together in one stable liquid.
- Regulatory track recordA registered product, with Eurasian Economic Union (EAEU) state registration and an export free-sale certificate.
- Intellectual propertyPatent application AU 2024219996 (view on the public register; opens in a new tab), filed 2024. Two further filings in preparation.
No single element is unique on its own. The combination, already proven in one commercial product, is what is hard to reproduce.
Process conditions compared
HMC against conventional route classes, as reported in published literature
| Route | Solvent-free | Process temperature | No high-energy step | Scale shown |
|---|---|---|---|---|
| Solvent-based | No | 20 to 70 °C | Varies | Industrial |
| Heat-based | Yes | 60 to 120 °C | Varies | Laboratory |
| High-energy | Yes | Ambient inlet, local heating | No | Industrial |
| Gentle routes, typical | Yes | Up to 70 °C | Yes | Laboratory |
| HMC | Yes | Room temperature, up to 30 °C | Yes | Commercial |
One proven product, five open fields.
HMC is proven in a commercial liquid supplement that carries omega-3 with vitamins C, D3 and E. The other fields are open for development with partners in each sector.
A proven commercial product.
A sugar-free liquid supplement carrying omega-3 (EPA and DHA) with vitamins C, D3 and E, uniting water-soluble and oil-soluble nutrients in one stable dosage form. It is designed for improved absorption and palatability, with no fishy aftertaste, and needs no cold chain. Children’s and family formats offer an alternative to capsules.
Reaching beyond supplements.
The same carrier can protect a fragile pharmaceutical active and combine hydrophilic and lipophilic actives in one system, a pairing conventional routes rarely allow. We pursue this as evidence-led, research-stage work with formulation partners, not as a finished medicine.
Delicate actives, kept stable.
Retinol, vitamin C and peptides are often the first ingredients to degrade in a formulation. Encapsulation could keep such delicate actives stable until application, in a light texture. We would develop this area with a beauty or personal-care partner.
Stable through demanding supply chains.
Animal-health products often travel long distances and are stored without refrigeration. A carrier that is stable at ambient temperature and fully redispersible after storage suits actives that must retain their quality until use. This early-stage area is open to animal-health partners.
Fortify without off-flavours.
Fortification usually involves a trade-off between added nutrition, flavour and shelf life. Encapsulated oils and sensitive nutrients could be incorporated without a fishy or bitter finish and without refrigerated storage. This is a broad, exploratory field for food and beverage manufacturers.
From carriers to surfaces.
If a carrier can protect what it holds, the same principle may apply to surfaces: functional coatings whose performance depends on keeping a sensitive agent stable and evenly distributed, including demanding uses such as low-observable defence finishes. This is an exploratory hypothesis, not a product, and lies outside anything we claim today.
License the platform. Partner to scale.
Engagement routes
Platform licensing
License HMC for your product category.
Technology transfer
We transfer the capability into your own operation.
Co-development
We co-develop your formulation, from active to finished carrier.
Virtual CDMO
We manage development and GMP manufacture at licensed partner sites, as one accountable partner.
Who we work with
- Supplement brands
- Pharmaceutical & biopharma formulation teams
- CDMOs
- API suppliers
- Consumer-health companies
- Strategic investors
From first enquiry to agreement.
A clear path from a first conversation to a working agreement, with confidentiality in place from the second step.
Enquiry
Tell us about your active, target format and market through the contact form.
Mutual NDA
We agree a mutual NDA so both sides can discuss the opportunity openly.
Feasibility review
We assess whether HMC suits your active, format and commercial goals.
Evaluation
You evaluate a sample formulation or data package under NDA.
Agreement
We agree the right route: licence, technology transfer, co-development or virtual CDMO.
Research programmes in progress.
Beyond our proven liquid supplement, which carries omega-3 with vitamins C, D3 and E, HMC supports several early-stage, evidence-led programmes. These are research directions rather than products or claims, and we welcome formulation, brand and research partners.
- Active exploration
Co-delivery systems
Carriers that hold hydrophilic, lipophilic and amphiphilic actives together, with built-in protection for oxidation-prone cargo.
- Research and partner stage
Pharma-grade & injectable routes
Applying the same ambient, solvent-free, single-vessel process to fragile APIs and injectable-route applications, in collaboration with partners and guided by evidence.
- Exploring
Beauty & skin actives
Topical delivery systems designed to keep delicate cosmetic actives stable from formulation through to application.
- Early frontier
Functional coatings
Investigating whether the same encapsulation principles can extend beyond delivery to engineered coatings. This work is speculative and at a very early stage.
Questions partners ask.
Short answers to the questions partners ask most often. Anything else, ask us directly.
Ask a questionVesiNex is a UK technology and licensing company. We license HMC, our green manufacturing platform for stable nanoliposomal carriers, and partner with brands, formulators and manufacturers. We are not a consumer retailer.
HMC (Hybrid Multiphasic Carriers) is a green platform that nano-encapsulates sensitive actives at ambient temperature, without solvents, in a single vessel. The carriers need no cold chain and are fully redispersible after storage.
Yes, in one commercial product: a sugar-free liquid supplement that carries omega-3 with vitamins C, D3 and E in one stable dosage form. Every other application field is exploratory and open for development with partners.
In an accelerated stability study (40 °C / 75 % RH, six months) by an independent analytical laboratory, a single batch of the registered multi-nutrient liquid kept 99.2 % of its initial EPA and 98.9 % of its initial DHA. The product is a registered food supplement, with Eurasian Economic Union (EAEU) state registration and an export free-sale certificate, both from 2024. See the evidence.
We operate as a virtual CDMO. We do not own manufacturing plants. We manage development and GMP manufacture of your formulation through our network of licensed partner sites, coordinating scale-up, batch production and quality oversight as one accountable partner.
Start with an enquiry. We then agree a mutual NDA, review feasibility for your active and format and, where it fits, share a sample formulation or data package for you to evaluate before any agreement. See how we work with partners.
A short outline of the active or actives you want to deliver, the target format and market, and indicative volumes and timelines. That is enough for an initial feasibility review.
Patent application AU 2024219996 (view on the public register; opens in a new tab), filed 2024. Two further filings in preparation.
Nutraceutical and wellness is proven. Pharmaceutical and API, beauty and cosmetic, veterinary and animal health, and food and beverage are exploratory fields open to partners. Functional coatings, including defence, is an early frontier, not a product.
No. We do not sell products, take orders or process payments. We work only with businesses, through platform licensing, technology transfer, co-development and virtual CDMO services.
Start a conversation.
Tell us how you would like to work with us. We route each enquiry to the right contact.
VesiNex Biosystems LtdRegistered in England and Wales, Company No. 17487028 (view on Companies House; opens in a new tab)Registered office: Bartle House, 9 Oxford Court, Manchester M2 3WQ, United Kingdominfo@vesinex.com